Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study
Open-label, no control groupDogs
- Design
- Open-label, no control group
- Subjects
- 160 dogs with moderate atopic dermatitis, at 39 clinics
- Dose used in the study
- Ultramicronised palmitoylethanolamide by mouth. A later review gives the dose as 10 mg/kg a day.
- Duration
- 8 weeks
- What was measured
- Owner-rated itch on a 10 cm scale, vet-rated skin lesion severity and a quality of life questionnaire over an 8-week trial in 160 dogs across 39 veterinary clinics
What the authors reported
This open-label study found:
- Mean itch scores fell from 5.7 cm to 3.63 cm (P < 0.0001).
- At week 8, 58% of dogs had a fall of more than 2 cm and 30% had absent to minimal itch.
- At week 8, 62% of dogs reached the remission score for skin lesions.
- At week 8, 45% reached the quality of life values of healthy dogs.
- Tolerability was rated good to excellent.
- Only four dogs had a reversible treatment-associated adverse event.
Limits of this study
Open-label with no control group. Itch in atopic dogs rises and falls, and owners knew the dogs were being treated. The entry was checked against the abstract only, which does not state the dose. Crossref lists the Italian Ministry of Instruction, University and Research as a funder.
Source
PubMed 26283633 · doi:10.1111/vde.12250
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.